Skip to main content
. 2022 May 10;53:102331. doi: 10.1016/j.redox.2022.102331

Fig. 6.

Fig. 6

CBS is downregulated in human hepatocellular carcinoma and correlates with better clinical prognosis. A, B) Relative CBS expression in hepatocellular carcinoma tumor versus peritumor tissues from TCGA and GSE14520 database, respectively. Data are shown as mean ​± ​SEM, ∗p ​< ​0.05, ∗∗p ​< ​0.01 showing better survival in high-CBS expressor patients. The panel was redrawn from data presented in Ref. [87]. C) Western blot analysis of CBS protein levels in 28 hepatocellular carcinoma tumor tissues and paired peritumor tissues. Data, shown as mean ​± ​SEM, show a significant downregulation of CBS in hepatocellular carcinoma ∗∗p ​< ​0.01. The panel was redrawn from data presented in Ref. [87]. D) Survival curve showing the impact of CBS expression on overall survival in hepatocellular carcinoma. ∗∗p ​< ​0.01 reflects better patient survival in high-CBS-expressing patients. The panel was redrawn from data presented in Ref. [84]. E) Survival curve showing the impact of CBS expression on overall survival in hepatocellular carcinoma from the LIHC dataset. ∗p ​< ​0.05 reflects better patient survival in high-CBS-expressing patients. The panel was redrawn from data presented in Ref. [55]. F) Survival curve showing the impact of CBS expression on overall survival in hepatocellular carcinoma from Atlas database (https://www.proteinatlas.org). ∗∗∗p ​< ​0.001 reflects better patient survival in high-CBS-expressing patients. G) Survival curve showing the impact of CBS expression on overall survival in hepatocellular carcinoma from TCGA database. p < 0.05 reflects the patient survival statistics. The panel was redrawn from data presented in Ref. [87].